Business Context and Reporting Period
This Form 8-K was filed by Capricor Therapeutics, Inc. on December 26, 2017, reporting events occurring on that date. The company is a Delaware corporation focused on regenerative medicine technologies, specifically extracellular vesicles (exosomes) and cardiosphere-derived cells (CDCs).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only specific financial figure disclosed is a reimbursement obligation of approximately $50,000 per agreement for attorneys' fees and filing fees related to additional patent rights.
Material Changes
On December 26, 2017, Capricor entered into two material definitive agreements with Cedars-Sinai Medical Center (CSMC):
- Exosomes License Amendment: A Fourth Amendment to the Exclusive License Agreement adding seven additional patent applications to the scope of the license.
- CDCs License Amendment: A Third Amendment to the Amended and Restated Exclusive License Agreement adding seven additional patent applications to the scope of the license.
Both amendments require Capricor to reimburse CSMC approximately $50,000 each for legal and filing costs associated with the new patent rights.
Outlook, Risks, and Related Parties
Related Party Transactions: CSMC holds more than 10% of Capricor Therapeutics' outstanding capital stock and is also a lessor under a lease agreement with the company. Dr. Eduardo Marbán, a significant shareholder (holding more than 10%), serves as the Director of the Cedars-Sinai Heart Institute and Co-founder/Scientific Advisory Board Chairman of Capricor.
Confidentiality: The company intends to seek confidential treatment for certain terms of these amendments due to competitively sensitive information regarding the patent applications.
Outlook: The filing does not contain specific financial guidance or management commentary on future operational performance beyond the execution of these license amendments.
Investor Verification Checklist
- Verify the total cash impact of the $100,000 combined reimbursement obligation ($50,000 per agreement) on current liquidity.
- Confirm the status of the seven additional patent applications added to each license and their potential commercial value.
- Review the full text of the License Amendments once filed as exhibits to understand any non-disclosed terms subject to confidential treatment.
- Assess the ongoing financial and operational relationship with CSMC, given its dual role as a major shareholder, licensor, and lessor.